Abstract
The genus Cissampelos comprises of 21 species which have a wide global distribution and various pharmacological activities such as analgesic and antipyretic, antiinflammatory, anti-allergic, bronchodilation, and immunomodulation among others. Several compounds, mainly alkaloids with differing biological activities have been isolated from this genus. We will highlight antipyretic activities, anti-inflammatory, antiallergic, bronchodilatory, and immunomodulatory activities. In addition, we applied ligand-based-virtual screening associated with structure-based-virtual screening of a small dataset of 63 secondary metabolites from the Cissampelos genus of an in-house data bank, in order to select compounds with potential anti-inflammatory activity. Affinities were observed for hayatine (26), isochondrondendrine (30), pelosine (52), sepeerine (59), and warifteine (63) to the inhibiting enzymes MAPK p38 alpha, PKC beta, PKC theta and PKC zeta. The cissampeloflavone compound (8) alone showed no potential inhibitory activity for PKC zeta, or affinity for the PKC alpha. The compounds can be used as starting points for further studies on structures with potential anti-inflammatory activity.
Keywords: Cissampelos, anti-inflammatory activity, virtual screening, multi-target, secondary metabolites, asthma.
Current Medicinal Chemistry
Title:Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity
Volume: 24 Issue: 16
Author(s): Mateus F. Alves, Marcus T. Scotti, Luciana Scotti*, Francisco Jaime Bezerra Mendonça, José M. B. Filho, Sílvia A. L. de Melo, Sócrates G. dos Santos and Margareth de F.F.M. Diniz
Affiliation:
- Health Sciences Center, Federal University of Paraíba, Campus I, 58051-970, João Pessoa- PB,Brazil
Keywords: Cissampelos, anti-inflammatory activity, virtual screening, multi-target, secondary metabolites, asthma.
Abstract: The genus Cissampelos comprises of 21 species which have a wide global distribution and various pharmacological activities such as analgesic and antipyretic, antiinflammatory, anti-allergic, bronchodilation, and immunomodulation among others. Several compounds, mainly alkaloids with differing biological activities have been isolated from this genus. We will highlight antipyretic activities, anti-inflammatory, antiallergic, bronchodilatory, and immunomodulatory activities. In addition, we applied ligand-based-virtual screening associated with structure-based-virtual screening of a small dataset of 63 secondary metabolites from the Cissampelos genus of an in-house data bank, in order to select compounds with potential anti-inflammatory activity. Affinities were observed for hayatine (26), isochondrondendrine (30), pelosine (52), sepeerine (59), and warifteine (63) to the inhibiting enzymes MAPK p38 alpha, PKC beta, PKC theta and PKC zeta. The cissampeloflavone compound (8) alone showed no potential inhibitory activity for PKC zeta, or affinity for the PKC alpha. The compounds can be used as starting points for further studies on structures with potential anti-inflammatory activity.
Export Options
About this article
Cite this article as:
Alves F. Mateus, Scotti T. Marcus, Scotti Luciana*, Mendonça Jaime Bezerra Francisco, Filho M. B. José, de Melo A. L. Sílvia, dos Santos G. Sócrates and de F.F.M. Diniz Margareth, Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity, Current Medicinal Chemistry 2017; 24 (16) . https://dx.doi.org/10.2174/0929867323666161227123411
DOI https://dx.doi.org/10.2174/0929867323666161227123411 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Oxazaphosphorines and its Clinical Implications
Current Pharmacogenomics TRPV1 Activation Prevents Renal Ischemia-Reperfusion Injury-Induced Increase in Salt Sensitivity by Suppressing Renal Sympathetic Nerve Activity
Current Hypertension Reviews Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Diabetic Medications in Pregnancy
Current Diabetes Reviews Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach
Current Medicinal Chemistry Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Current Pharmaceutical Design Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Editorial from Editorial Board Member [ Thoughts on Impact Factors and Editing of Medical Journals ]
Inflammation & Allergy - Drug Targets (Discontinued) From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Anti-inflammatory Activities of Phenoxyphenyl Ureas Mediated by Inhibition of p38 Kinase
Current Enzyme Inhibition Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line
Current Drug Discovery Technologies Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Current Rheumatology Reviews Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews